27.98

4.93% 1.335

Castle Biosciences Inc (CSTL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CSTL Giù? Forum Previsione

Precedente Chiudi:

$26.65

Aprire:

$26.82

Volume 24 ore:

45,603

Relative Volume:

0.13

Capitalizzazione di mercato:

$746.39M

Reddito:

$219.79M

Utile/perdita netta:

$-57.47M

Rapporto P/E:

-8.3537

EPS:

-3.35

Flusso di cassa netto:

$-19.25M

1 W Prestazione:

+3.19%

1M Prestazione:

-10.94%

6M Prestazione:

+31.54%

1 anno Prestazione:

+27.35%

Intervallo 1D:

$26.82

$28.11

Intervallo di 1 settimana:

$25.82

$28.11

Portata 52W:

$16.96

$35.84

Castle Biosciences Inc Stock (CSTL) Company Profile

Nome

Castle Biosciences Inc

Settore

Healthcare (1188)

Industria

Diagnostics & Research (56)

Telefono

866-788-9007

Indirizzo

505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX

Dipendente

710

Cinguettio

@castlebio

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

CSTL's Discussions on Twitter

Confronta CSTL con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CSTL Castle Biosciences Inc	28.10	746.39M	219.79M	-57.47M	-19.25M	-2.15
TMO Thermo Fisher Scientific Inc	524.35	198.99B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	231.05	165.80B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	135.06	38.37B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	198.07	35.67B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	418.15	33.85B	3.84B	866.24M	792.60M	10.37

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-14	Iniziato	Guggenheim	Buy
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-07	Iniziato	Stephens	Overweight
2021-04-30	Iniziato	Lake Street	Buy
2020-11-10	Iniziato	KeyBanc Capital Markets	Overweight
2019-12-27	Reiterato	Canaccord Genuity	Buy
2019-08-19	Iniziato	BTIG Research	Buy
2019-08-19	Iniziato	Canaccord Genuity	Buy
2019-08-19	Iniziato	Robert W. Baird	Outperform
2019-08-19	Iniziato	SVB Leerink	Outperform

Mostra tutto

Castle Biosciences Inc Borsa (CSTL) Ultime notizie

08:43 AM

Castle Biosciences' (CSTL) Overweight Rating Reaffirmed at Stephens - MarketBeat

08:43 AM

08:02 AM

Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock - Benzinga

08:02 AM

Dec 31, 2024

Brokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - Defense World

Dec 31, 2024

Dec 29, 2024

Barclays PLC Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 29, 2024

Geode Capital Management LLC Increases Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 29, 2024

Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 29, 2024

Dec 28, 2024

Analysts Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - MarketBeat

Dec 28, 2024

Dec 27, 2024

Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Holdings Lifted by Franklin Resources Inc. - MarketBeat

Dec 27, 2024

Dec 24, 2024

Castle Biosciences reports preliminary data from atopic dermatitis test study - Yahoo! Voices

Dec 24, 2024

State Street Corp Acquires 60,924 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 24, 2024

Castle Biosciences to launch AD test by end of 2025 - Investing.com Canada

Dec 24, 2024

Dec 23, 2024

Castle Biosciences Unveils Promising Early Data for Revolutionary Atopic Dermatitis Test - StockTitan

Dec 23, 2024

Principal Financial Group Inc. Buys 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 23, 2024

Dec 19, 2024

Castle Biosciences CEO Derek Maetzold sells $265,357 in shares - Investing.com India

Dec 19, 2024

Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 9,364 Shares of Stock - MarketBeat

Dec 19, 2024

Castle Biosciences CEO Derek Maetzold sells $265,357 in shares By Investing.com - Investing.com South Africa

Dec 19, 2024

The True Test of Success - BOSS Magazine

Dec 19, 2024

Castle Biosciences Awards Major RSU Package to 135 Employees in Strategic Retention Move - StockTitan

Dec 19, 2024

Dec 18, 2024

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade - MSN

Dec 18, 2024

Dec 17, 2024

Castle Biosciences CEO Derek Maetzold sells $750,296 in stock - Investing.com India

Dec 17, 2024

Short Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Expands By 7.6% - MarketBeat

Dec 17, 2024

Dec 16, 2024

Captrust Financial Advisors Decreases Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Dec 16, 2024

Dec 14, 2024

Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why - MSN

Dec 14, 2024

Dec 12, 2024

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire

Dec 12, 2024

Castle Biosciences' DecisionDx-Melanoma Test Validated in Landmark Meta-Analysis for Cancer Survival Prediction - StockTitan

Dec 12, 2024

Dec 11, 2024

Charles Schwab Investment Management Inc. Boosts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 11, 2024

Dec 09, 2024

Castle Biosciences CEO Derek Maetzold sells $160,741 in shares - Investing.com India

Dec 09, 2024

Castle Biosciences CEO Derek Maetzold sells $160,741 in shares By Investing.com - Investing.com UK

Dec 09, 2024

Dec 07, 2024

Point72 Asset Management L.P. Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 07, 2024

Dec 06, 2024

Castle Biosciences director Daniel Bradbury sells $243,692 in stock By Investing.com - Investing.com Canada

Dec 06, 2024

Dec 05, 2024

Castle Biosciences director Daniel Bradbury sells $243,692 in stock - Investing.com India

Dec 05, 2024

Jacobs Levy Equity Management Inc. Has $14.16 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Dec 05, 2024

Dec 04, 2024